Successful use of trastuzumab deruxtecan in hepatic visceral crisis secondary to metastatic HER2-low breast cancer

•Up to 20 % of patients with metastatic breast cancer develop hepatic visceral crisis, a life-threatening condition that implies impending liver failure and death.•Combination chemotherapy is recommended for hepatic visceral crisis however the outcomes are generally dismal.•Trastuzumab deruxtecan is...

Full description

Bibliographic Details

Published in:	Current problems in cancer. Case reports Vol. 20; p. 100392
Main Authors:	Kapoor, Nilesh, Su, Malcolm, Horadam, Rochelle, Klemow, Dawn, Syed, Samira
Format:	Journal Article
Language:	English
Published:	Elsevier Inc 01.12.2025
Subjects:	Antibody-drug conjugate Hematology, Oncology, and Palliative Medicine Hepatic visceral crisis HER2-low Metastatic breast cancer Trastuzumab deruxtecan Metastatic breast cancer HER2-low Trastuzumab deruxtecan Hepatic visceral crisis Antibody-drug conjugate
ISSN:	2666-6219, 2666-6219
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!